NCT06549530View on ClinicalTrials.gov

Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children from 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections

PHASE2RecruitingINTERVENTIONAL
Enrollment

460

Participants

Timeline

Start Date

October 21, 2024

Primary Completion Date

June 12, 2025

Study Completion Date

May 7, 2026

Conditions
Monkeypox (Mpox)
Interventions
DRUG

MVA-BN

All participants will receive 2 vaccinations of the same dose of MVA-BN vaccine 4 weeks apart (standard regimen).

Trial Locations (3)

Unknown

RECRUITING

University of Kinshasa, Kinshasa

RECRUITING

Uganda Virus Research Institute, Entebbe

RECRUITING

Epicentre Mbarara Research Centre, Mbarara

Sponsors

Lead Sponsor

Bavarian Nordic
All Listed Sponsors
collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

lead

Bavarian Nordic

INDUSTRY

NCT06549530 - Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children from 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections | Biotech Hunter | Biotech Hunter